Sponsored by LFG Equities Corp and Disseminated on Behalf of InMed Pharmaceuticals
Finviz has the Float a TINY 1.2 Mill, highlighting the ability to easily move
InMed’s strong pipeline of treatments, from preclinical stages through Phase 2 trials, showcases the company’s long-term potential and strategic foresight
INM’s Subsidiary Baymedica is Generating Nearly $5Mill in Revenues
Check Out the Investor Presentation HERE
_________________________
Hello Everyone,
InMed Pharmaceuticals is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s disease and ocular and dermatological indications. InMed Pharmaceuticals is not just another biotech firm; it’s a company with the potential to redefine the treatment landscape for Alzheimer’s disease.
INM is an extremely unique hybrid company. They have several pharmaceutical programs supported by a revenue generating business.
INM uses a patented form of cannabinoid molecules. These molecules originally found in Cannabis have long been known for its medicinal properties, including its ability to reduce inflammation, improve symptoms of chronic diseases, and even show potential in cancer treatment.
Several studies have pointed to the neuroprotective effects of cannabinoids which protect brain cells from damage, preserving cognition with is incredibly important for neurodegenerative diseases such as Alzheimer’s. However, the use of cannabinoids in medicine has been limited due to legal and regulatory concerns.
InMed is addressing this challenge by modifying natural cannabinoids to create super effective molecules that could offer even greater therapeutic benefits. These cannabinoid molecules are naturally occurring… however when modified by InMed, their effect could potentially be a game changer for Alzheimer’s disease.
In fact, their treatment, INM-901, is the result of this innovative approach. And what’s incredible is InMed has patented the actual molecules in their treatment, protecting themselves against competitors using identical compounds.
This is the exact type of approach that could get Big Pharma to become a customer rather than a competitor.
Thanks to its unique patented molecules and INM-901 treatment… the potential for success is sky high with this company.
And as the race to tackle Alzheimer’s intensifies, InMed’s innovative approach and strategic positioning make it a standout player in a rapidly growing market.
We know this one can FLY. Just a few weeks ago in early June it ran to 8 bucks on $450 Mill with zero news to speak of. It just got going with some momentum.
INM has the potential to move because it roughly has a market cap OF $3.3M give or take. The valuation might be what really stands out to you. If you can believe it they are sitting below their current cash and have a profitable subsidiary generating roughly $5 million in annual revenue. What INM brings to the table for their investors is exposure to a full pharmaceutical pipeline and commercial subsidiary at essentially no enterprise value.
INM has 3 therapeutic programs in development. The most promising asset may be INM-901, a proprietary oral small molecule targeting Alzheimer’s disease. This represents one of the largest and most underserved markets in medicine.
INM Alzheimer’s preclinical program Highlights:
• Addressing multiple pathologies related to Alzheimer’s Disease
• Reduce neuroinflammation and enhance neuronal functioning in the brain potentially reversing the damage caused by Alzheimer’s disease.
• Importantly, INM-901 may be delivered orally where most drugs in Alzheimer’s need to be administered through IV, which can be very costly and challenging.
• Safely and effectively cross the blood/brain barrier, delivering the drug molecule directly to the brain.
• Successfully crossing the blood/brain barrier is a major challenge to the industry and is important in offering treatment to diseases such as Alzheimer’s.
• Demonstrates a trend in improvement in cognitive function and memory, locomotor activity, anxiety-based behavior and sound awareness in vivo studies– All major hallmarks of this devastating disease.
• Statistically significant reductions in inflammatory and neurodegeneration biomarkers
• Cost-effective, which is increasingly important as the healthcare system looks to balance innovation with accessibility
INM-089: Advancing a Novel Approach in Dry AMD
• INM-089 is InMed’s proprietary small molecule drug candidate targeting dry age-related macular degeneration (AMD)—a condition with no FDA-approved treatment options and affecting over 150 million people globally.
Completed a phase 2 clinical trial in the treatment of Epidermolysis bullosa – Currently seeking strategic partnership for further advancement.
BAYMEDICA
INM Has Built in Insurance with revenue generating & profitable subsidiary BayMedica
While many preclinical-stage biotech companies are entirely reliant on external capital, InMed reduces investor risk through BayMedica, its commercial arm.
This division is cash-flow positive and positioned for potential divestiture, spin-out, or growth partnership—unlocking hidden value.
Undervalued: With a market cap less than its cash position, active revenue stream, disease-modifying Alzheimer’s drug candidate, InMed (NASDAQ: INM) represents a rare value in today’s biotech landscape.
One of the biggest challenges with current Alzheimer’s treatments is while they may slow the rate of cognitive decline, none have been shown to halt or reverse its progression.
Not to mention some of these recently-approved drugs come with major treatment limitations that are incredibly costly and inconvenient for patients.
In fact, most of these treatments only focus on one thing; reducing Amyloid beta plaque.
However, new research suggests this plaque is not the cause of Alzheimer’s and instead is a symptom.[9] That means hundreds of millions of dollars and decades of patient trials haven’t been able to offer a comprehensive cure. In fact, new research suggest the most effective way to treat Alzheimer’s will require a multitude of therapies, not a silver bullet.
This is where InMed’s unique approach comes in!
Not only do their previous preclinical studies show a reduction in amyloid beta plaque but it also shows the potential to be diseases modifying by:
- Addressing multiple pathologies related to Alzheimer’s Disease
- Reduce neuroinflammation and enhance neuronal functioning in the brain potentially reversing the damage caused by Alzheimer’s disease.
- Importantly, INM-901 may be delivered orally where most drugs in Alzheimer’s need to be administered through IV, which can be very costly and challenging.
- Safely and effectively cross the blood/brain barrier, delivering the drug molecule directly to the brain.
- Successfully crossing the blood/brain barrier is a major challenge to the industry and is important in offering treatment to diseases such as Alzheimer’s.
- Demonstrates a trend in improvement in cognitive function and memory, locomotor activity, anxiety-based behavior and sound awareness – All major hallmarks of this devastating disease.
But one of the most exciting developments for INM is the data supporting the growth of neurites. This allows for better cell to cell to communicate within the brain.
In simple terms, this development may indicate the potential to reverse neuronal damage.
An incredible feat that has not been seen in any other treatment available today.
You read that right. This tiny $3M microcap is demonstrating cutting edge developments in Alzheimer’s treatments.
Also the fact that this molecule can be formulated orally is a HUGE advantage. Current treatment options utilizing large molecules often come with serious side effects, such as brain inflammation and bleeding, necessitating periodic brain scans—typically once or twice annually—to monitor these risks. In contrast, small molecule drug candidates present numerous advantages over existing therapies. InMed aims to develop an effective, disease-modifying treatment that is orally administered, ensuring greater accessibility for patients.
NEWS
Jun 13, 2025
InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
May 12, 2025
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Feb 12, 2025
Feb 3, 2025
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds
Jan 22, 2025
Jan 21, 2025
InMed Announces Results of 2024 Annual General Meeting
Dec 18, 2024
InMed Enters Into Standby Equity Purchase Agreement
Dec 17, 2024
InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System
Nov 19, 2024
InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
Nov 14, 2024
MANAGEMENT
Eric A. Adams, MIBS
Chief Executive Officer & President
Eric A. Adams was appointed Chief Executive Officer, President and Director of InMed Pharmaceuticals, Inc. in June 2016. During his tenure at InMed, he has reconstituted the Board of Directors and the Executive management team and has raised more than $35M in
capital to fund operations. Mr. Adams is a seasoned biopharmaceutical executive with more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers & acquisitions, licensing and corporate governance.Mr. Adams previously served as CEO at enGene Inc., where he oversaw its transformation from a nascent start-up into a venture capital-backed leader in gene therapy. Prior to enGene, Mr. Adams held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL), and Fresenius AG (Germany). As the previous Chairman of BIOTECanada’s Emerging Company Advisory Board, and for his extensive generosity in mentoring biotech entrepreneurs, Mr. Adams is well-respected within the Canadian biotech industry as a strategic advisor to a number of early-stage biotech companies. He is a dual citizen of Canada and the United States, and holds a Masters of International Business from the University of South Carolina and a Bachelor’s Degree in Chemistry from the University of Southern Indiana.
Michael Woudenberg, P.Eng.
Chief Operating Officer
Mr. Woudenberg joined InMed with more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He brings valuable expertise in the development, technology transfer and commercialization of
active pharmaceutical ingredients (APIs) and drug products. Prior to joining InMed in 2018, Mr. Woudenberg held various positions within 3M, Cardiome Pharma, Arbutus Biopharma and most recently as the Managing Director of Phyton Biotech, LLC. His experience includes process and formulation development from lab/pre-clinical products through the various stages of clinical development to validated and successfully approved and inspected commercial APIs and drug products. Additionally, he has extensive experience with regards to regulatory inspections (e.g. FDA, European, Australian, Korean, Japanese, Canadian) and their related chemistry, manufacturing and control requirements from clinical to commercial production of approved products.Mr. Woudenberg received his Bachelor of Science, Chemistry and Bachelor of Engineering Science, Chemical at Western University of London, Ontario, Canada.
Netta Jagpal, CPA
Chief Financial Officer
Ms. Jagpal joins InMed with over 20 years of experience in financial leadership roles, primarily in the biotech industry. Prior to InMed, Ms. Jagpal served as Vice President, Financial Reporting & Compliance for D-Wave Systems Inc. (NYSE: QBTS) where she led a finance team through the initial public offering process.
Prior to D-Wave, Netta spent 11 years at Zymeworks Inc. (NYSE: ZYME), a leading Vancouver based clinical stage biopharmaceutical company, in various financial roles including Senior Director, Finance & Corporate Controller. Netta has also previously held roles at Angiotech Pharmaceuticals, Inc. (NASDAQ: ANP) and Ernst & Young. Netta is a Chartered Professional Accountant with the Institute of Chartered Accountants of British Columbia and holds a Bachelor of Business Administration degree in Accounting and Organization Behaviour from Simon Fraser University.
Eric C. Hsu, PhD
Senior Vice President, Pre-Clinical Research & Development
Dr. Hsu joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. Prior to joining InMed, he held various positions within enGene Inc., including V.P. of Research and V.P. of Scientific Affairs and Operations.
Dr. Hsu’s experience includes a wide array of activities, including benchtop research, formulation development and manufacturing process development, as well as patent prosecution, vendor contract negotiations and execution, and research partnerships. He is also responsible for expanding product pipelines, and managing R&D budgets and timelines. Dr. Hsu is considered to be an expert in gene transfer and gene expression using vector systems.Dr. Hsu received his Doctorate from the Department of Medical Biophysics at the University of Toronto and his Bachelor’s degree from McGill University.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF SIX THOUSAND THREE HUNDRED SEVENTY FIVE USD BY LFG EQUITIES CORP FOR A ONE DAY INM AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.